Upgrade to SI Premium - Free Trial

Jazz Pharmaceuticals (JAZZ) PT Lowered to $174 at RBC Capital

August 1, 2024 6:26 AM
RBC Capital analyst Daniel Busb lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $174.00 (from $175.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles